1. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth 2016; 35: 1-12. doi: 10.1016/j.jclinane.2016.06.018.
2.
Teng IC, Chang YJ, Lin YT, Chu CC, Chen JY, Wu ZF. Sugammadex induced bradycardia and hypotension: a case report and literature review. Med (United States) 2021; 100: e26796. doi: 10.1097/MD.0000000000026796.
3.
Sanoja IA, Toth KS. Profound bradycardia and cardiac arrest after sugammadex administration in a previously healthy patient: a case report. A A Pract 2019; 12: 22-24. doi: 10.1213/XAA.0000000000000834.
4.
Pereira AV, Oliveira RR, Esteves C, Coutinho MA. Cardiac arrest following sugammadex administration. Anaesth Rep 2023; 11: e12233. doi: 10.1002/anr3.12233.
5.
Oliveira C, Marques C, Simões V, Spencer L, Poeira R, Casteleira M. Severe bradycardia and asystole associated with sugammadex: case report. Brazilian J Anesthesiol 2019; 69: 218-221 [Article in Portuguese]. doi: 10.1016/j.bjan.2018.09.010.
6.
Fierro C, Medoro A, Mignogna D, Porcile C, Ciampi S, Foderà E, et al. Severe hypotension, bradycardia and asystole after sugammadex administration in an elderly patient. Medicina (Kaunas) 2021; 57: 79. doi: 10.3390/medicina57010079.
7.
Bhavani SS. Severe bradycardia and asystole after sugammadex. Br J Anaesth 2018; 121: 95-96. doi: 10.1016/j.bja.2018.02.036.
8.
Bilgi M, Demirhan A, Akkaya A, Tekelioglu U, Kocoglu H. Sugammadex associate persistant bradycardia. Int J Med Sci Public Heal 2014; 3: 372-374. doi: 10.5455/ijmsph.2013.251220131.
9.
Merck Sharp & Dohme. Bridion Summary of Product Characterisitcs. Available at: https://www.ema.europa.eu/en/documents/product-information/bridion-epar-product-information_en.pdf.
10.
Merck Sharp & Dohme Corporation. Sugammadex Advisory Committee Briefing Document. 2015. Available at: https://www.fdanews.com/ext/resources/files/11-15/110615-merck.pdf?1520874794.
11.
Kadiyala M, Gedulig T, Banik RK. Adverse effects of sugammadex on the cardiovascular system. Cureus 2023; 15: e34728. doi: 10.7759/cureus.34728.
12.
Iwade M, Ohashi A, Kamiya M, Ozaki M. Transient complete atrioventricular block resulted from cardiac anaphylaxis caused by sugammadex. Emerg Med Open Access 2018; 08: 8-10. doi: 10.4172/2165-7548.1000370
13.
Obara S, Kurosawa S, Honda J, Oishi R, Iseki Y, Murakawa M. Cardiac arrest following anaphylaxis induced by sugammadex in a regional hospital. J Clin Anesth 2018; 44: 62-63. doi: 10.1016/j.jclinane.2017.11.003.
14.
Yanai M, Ariyoshi K. Two cardiac arrests that occurred after the administration of sugammadex: a case of Kounis syndrome. Case Rep Emerg Med 2020; 6590101. doi: 10.1155/2020/6590101.
15.
Yoshida T, Sumi C, Uba T, Miyata H, Umegaki T, Kamibayashi T. A rare case of atropine-resistant bradycardia following sugammadex administration. JA Clin Rep 2020; 6: 18. doi: 10.1186/s40981-020-00326-7.
16.
Boo KY, Park SH, Park SK, Na C, Kim HJ. Cardiac arrest due to coronary vasospasm after sugammadex administration – a case report. Korean J Anesthesiol 2023; 76: 72-76. doi: 10.4097/kja.22335.
17.
Ko MJ, Kim YH, Kang E, Lee BC, Lee S, Jung JW. Cardiac arrest after sugammadex administration in a patient with variant angina: a case report. Korean J Anesthesiol 2016; 69: 514-517. doi: 10.4097/kjae.2016.69.5.514.
18.
Hawkins J, Khanna S, Argalious M. Sugammadex for reversal of neuromuscular blockade: uses and limitations. Curr Pharm Des 2019; 25: 2140-2148. doi: 10.2174/1381612825666190704101145.
19.
Zhang C, Wang Z, Zhang J, Qiu H, Sun Y, Yang L, et al. Competitive inhibition of the nondepolarizing muscle relaxant rocuronium on nicotinic acetylcholine receptor channels in the rat superior cervical ganglia. J Cardiovasc Pharmacol 2014; 63: 428-433. doi: 10.1097/FJC.0000000000000063.
20.
Osaka Y, Shimada N, Satou M, Masuda T, Ando T, Kozono Y, et al. A case of atrioventricular block (Wenckebach type) induced by sugammadex. J Anesth 2012; 26: 627-628. doi: 10.1007/s00540-012-1390-x.
21.
Abdelrahim MT, Kassels AC, Stark CW, Roberts CJ, Vogt JA, Ebert TJ. A case report of acute onset and rapid resolution of atrioventricular block after sugammadex: is the autonomic system involved? A A Pract 2023; 17: e01683. doi: 10.1213/XAA.0000000000001683.
22.
Saito I, Osaka Y, Shimada M. Transient third-degree AV block following sugammadex. J Anesth 2015; 29: 641. doi: 10.1007/s00540-015-1980-5.
23.
Kapoor M. Cardiovascular adverse effects of sugammadex. J Anaesthesiol Clin Pharmacol 2020; 36: 469-470. doi: 10.4103/joacp.JOACP_132_20.
24.
Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: An international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109: 188-197. doi: 10.1097/ALN.0b013e31817f5bc7.
25.
De Boer H, Driessen J, Marcus M, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-244. doi: 10.1097/01.anes.0000270722.95764.37.
26.
Kam PJ de, Kuijk J van, Smeets J, Thomsen T, Peeters P. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther 2012; 50: 595-604. doi: 10.5414/CP201693.
27.
Lohmeier SJ, Powers DB. Sugammadex-associated asystole in young obese patient: case report. Oral Maxillofac Surg Cases 2022; 8: 100271. doi: https://doi.org/10.1016/j.omsc.2022.100271.
28.
Gajewski M, Esochaghi S. Transient asystole after sugammadex administration for immediate reversal of deep blockade while on dexmedetomidine infusion in a super obese patient. Case Rep Anesthesiol 2019; 2019: 2709568. doi: 10.1155/2019/2709568.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
